LinkedIn Profile

Access StemCell2MAX historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:stemcell2max 9459955 Jun 3rd, 2019 12:00AM StemCell2MAX 351 3.00 Open Biotechnology Jun 3rd, 2019 12:30PM Jun 3rd, 2019 12:30PM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. Open Biotechnology, Research, Stem cell, Healthcare, Hematopoietic Open StemCell2MAX
private:stemcell2max 9459955 Feb 17th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 16th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 15th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 14th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 13th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 12th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 11th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 10th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX
private:stemcell2max 9459955 Feb 9th, 2018 12:00AM StemCell2MAX 319 5.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but these are scarce resulting in limited transplants, patient death and limitations at research level. StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers. Research market: Currently, StemCell2MAX markets StemCell2MAX Mix for research use only with a growing sales track record, both in EU and USA. Clinical market: Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing StemCell2MAX Med for the clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.